Newer parameters of the octreotide test in patients with acromegaly.

Acromegaly IGF-I Octreotide test Somatostatin analog

Journal

Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578

Informations de publication

Date de publication:
24 Nov 2023
Historique:
accepted: 23 10 2023
medline: 24 11 2023
pubmed: 24 11 2023
entrez: 24 11 2023
Statut: aheadofprint

Résumé

Predicting the therapeutic effects of first-generation somatostatin receptor ligands (fg-SRLs) is important when assessing or planning effective treatment strategies in patients with acromegaly. The oft-used maximum growth hormone (GH) suppression rate parameter of the octreotide test has a suboptimal predictive value. Therefore, this study explored newer parameters of the octreotide test for predicting the therapeutic effect of long-acting fg-SRLs. In this single-center retrospective study, the octreotide test parameters and the therapeutic effects of fg-SRL at 3 months were investigated in 45 consecutive treatment-naïve patients with acromegaly between April 2008 and March 2023. Additionally, the relationship between the octreotide test parameters and the therapeutic effects of fg-SRLs was investigated. Tumor shrinkage was evaluated based on changes in the longitudinal diameter of the macroadenomas. The area GH suppression rate-time under the curve (AUC) and the time to nadir GH level were calculated and compared with the maximum GH suppression rate. The AUC estimated reductions in serum insulin-like growth factor I, and tumor shrinkage. The time to nadir GH level predicted tumor shrinkage more robustly than the maximum GH suppression rate in patients with macroadenoma. The AUC and time to nadir GH level may potentially be newer parameters of the octreotide test for estimating the therapeutic effect of fg-SRLs.

Identifiants

DOI: 10.1007/s11102-023-01362-z PMID: 37999819
pubmed: 37999819
doi: 10.1007/s11102-023-01362-z
pii: 10.1007/s11102-023-01362-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Fleseriu M, Langlois F, Lim DST et al (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10:804–826. https://doi.org/10.1016/S2213-8587(22)00244-3
doi: 10.1016/S2213-8587(22)00244-3 pubmed: 36209758
Giustina A, Barkan A, Beckers A et al (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab 105:e937–e946. https://doi.org/10.1210/clinem/dgz096
doi: 10.1210/clinem/dgz096
Melmed S, Bronstein MD, Chanson P et al (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14:552–561. https://doi.org/10.1038/s41574-018-0058-5
doi: 10.1038/s41574-018-0058-5 pubmed: 30050156 pmcid: 7136157
Cuevas-Ramos D, Carmichael JD, Cooper O et al (2015) A structural and functional acromegaly classification. J Clin Endocrinol Metab 100:122–131. https://doi.org/10.1210/jc.2014-2468
doi: 10.1210/jc.2014-2468 pubmed: 25250634
Carmichael JD, Bonert VS, Nuño M et al (2014) Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab 99:1825–1833. https://doi.org/10.1210/jc.2013-3757
doi: 10.1210/jc.2013-3757 pubmed: 24606084 pmcid: 4010703
Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24:238–246. https://doi.org/10.1016/j.tem.2012.11.007
doi: 10.1016/j.tem.2012.11.007 pubmed: 23270713
Fleseriu M, Biller BMK, Freda PU et al (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24:1–13. https://doi.org/10.1007/s11102-020-01091-7
doi: 10.1007/s11102-020-01091-7 pubmed: 33079318
Ilie M-D, Tabarin A, Vasiljevic A et al (2022) Predictive factors of somatostatin receptor ligand response in acromegaly—a prospective study. J Clin Endocrinol Metab 107:2982–2991. https://doi.org/10.1210/clinem/dgac512
doi: 10.1210/clinem/dgac512 pubmed: 36136828
Lamberts SW, Uitterlinden P, Schuijff PC, Klijn JG (1988) Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical “cure.” Clin Endocrinol 29:411–420. https://doi.org/10.1111/j.1365-2265.1988.tb02890.x
doi: 10.1111/j.1365-2265.1988.tb02890.x
Puig Domingo M (2015) Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol 83:3–14. https://doi.org/10.1111/cen.12731
doi: 10.1111/cen.12731
Gadelha MR, Wildemberg LE, Kasuki L (2022) The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 107:297–308. https://doi.org/10.1210/clinem/dgab726
doi: 10.1210/clinem/dgab726 pubmed: 34618894
Gilbert JA, Miell JP, Chambers SM et al (2005) The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin Endocrinol 62:742–747. https://doi.org/10.1111/j.1365-2265.2005.02278.x
doi: 10.1111/j.1365-2265.2005.02278.x
Halperin I, Nicolau J, Casamitjana R et al (2008) A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Horm Metab Res 40:422–426. https://doi.org/10.1055/s-2008-1065339
doi: 10.1055/s-2008-1065339 pubmed: 18393173
Taboada GF, Donangelo I, Guimarães RFC et al (2005) Acute test with subcutaneous octreotide as a predictor of the response to treatment with octreotide LAR. Arq Bras Endocrinol Metabol 49:390–395. https://doi.org/10.1590/s0004-27302005000300010
doi: 10.1590/s0004-27302005000300010 pubmed: 16543993
de Herder WW, Taal HR, Uitterlinden P et al (2005) Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol 153:67–71. https://doi.org/10.1530/eje.1.01935
doi: 10.1530/eje.1.01935 pubmed: 15994747
Colao A, Pivonello R, Auriemma RS et al (2008) Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. J Clin Endocrinol Metab 93:3436–3442. https://doi.org/10.1210/jc.2008-0424
doi: 10.1210/jc.2008-0424 pubmed: 18593770
Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32:247–271. https://doi.org/10.1210/er.2010-0002
doi: 10.1210/er.2010-0002 pubmed: 21123741
Petersenn S, Houchard A, Sert C et al (2020) Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary 23:171–181. https://doi.org/10.1007/s11102-019-01020-3
doi: 10.1007/s11102-019-01020-3 pubmed: 31879842
Giustina A, di Filippo L, Uygur MM, Frara S (2023) Modern approach to resistant acromegaly. Endocrine 80:303–307. https://doi.org/10.1007/s12020-023-03317-7
doi: 10.1007/s12020-023-03317-7 pubmed: 36790521
Katznelson L, Laws ER Jr, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933–3951. https://doi.org/10.1210/jc.2014-2700
doi: 10.1210/jc.2014-2700 pubmed: 25356808
Heck A, Ringstad G, Fougner SL et al (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol 77:72–78. https://doi.org/10.1111/j.1365-2265.2011.04286.x
doi: 10.1111/j.1365-2265.2011.04286.x
Hagiwara A, Inoue Y, Wakasa K et al (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228:533–538. https://doi.org/10.1148/radiol.2282020695
doi: 10.1148/radiol.2282020695 pubmed: 12819334
Isojima T, Shimatsu A, Yokoya S et al (2012) Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J 59:771–780. https://doi.org/10.1507/endocrj.ej12-0110
doi: 10.1507/endocrj.ej12-0110 pubmed: 22673406
Colao A, Ferone D, Lastoria S et al (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81:2356–2362. https://doi.org/10.1210/jcem.81.6.8964877
doi: 10.1210/jcem.81.6.8964877 pubmed: 8964877
Yamamoto M, Fukuoka H, Iguchi G et al (2015) The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study. Pituitary 18:343–351. https://doi.org/10.1007/s11102-014-0580-y
doi: 10.1007/s11102-014-0580-y pubmed: 24947684
Coopmans EC, Korevaar TIM, van Meyel SWF et al (2020) Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 105:2964–2974. https://doi.org/10.1210/clinem/dgaa387
doi: 10.1210/clinem/dgaa387
Giustina A, Mazziotti G, Torri V et al (2012) Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7:e36411. https://doi.org/10.1371/journal.pone.0036411
doi: 10.1371/journal.pone.0036411 pubmed: 22574156 pmcid: 3344864
Casar-Borota O, Heck A, Schulz S et al (2013) Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab 98:E1730–E1739. https://doi.org/10.1210/jc.2013-2145
doi: 10.1210/jc.2013-2145 pubmed: 24092823
Wang M, Shen M, He W et al (2016) The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly. Endocr J 63:819–834. https://doi.org/10.1507/endocrj.EJ16-0175
doi: 10.1507/endocrj.EJ16-0175 pubmed: 27432816
Karavitaki N, Botusan I, Radian S et al (2005) The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol 62:282–288. https://doi.org/10.1111/j.1365-2265.2004.02191.x
doi: 10.1111/j.1365-2265.2004.02191.x
Bianchi A, Valentini F, Iuorio R et al (2013) Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res 32:40. https://doi.org/10.1186/1756-9966-32-40
doi: 10.1186/1756-9966-32-40 pubmed: 23799893 pmcid: 3695848
Chiloiro S, Costa D, Lauretta R et al (2022) Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly. Endocrine 78:343–353. https://doi.org/10.1007/s12020-022-03158-w
doi: 10.1007/s12020-022-03158-w pubmed: 35986839 pmcid: 9584996
Chiloiro S, Giampietro A, Mirra F et al (2021) Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol 184:217–229. https://doi.org/10.1530/EJE-20-0767
doi: 10.1530/EJE-20-0767 pubmed: 33136550
Gadelha MR, Bronstein MD, Brue T et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2:875–884. https://doi.org/10.1016/S2213-8587(14)70169-X
doi: 10.1016/S2213-8587(14)70169-X pubmed: 25260838
Cozzi R, Attanasio R, Montini M et al (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090–3098. https://doi.org/10.1210/jc.2003-030110
doi: 10.1210/jc.2003-030110 pubmed: 12843148
Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34:228–252. https://doi.org/10.1016/j.yfrne.2013.07.005
doi: 10.1016/j.yfrne.2013.07.005 pubmed: 23872332
Carlsen SM, Lund-Johansen M, Schreiner T et al (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93:2984–2990. https://doi.org/10.1210/jc.2008-0315
doi: 10.1210/jc.2008-0315 pubmed: 18492760
Fleseriu M, Hoffman AR, Katznelson L, Neuroendocrine AACE, Committee PS (2015) American association of clinical endocrinologists and American college of endocrinology disease state clinical review: management of acromegaly patients: what is the role of pre-operative medical therapy? Endocr Pract 21:668–673. https://doi.org/10.4158/EP14575.DSCR
doi: 10.4158/EP14575.DSCR pubmed: 26135961
Yang C, Li G, Jiang S et al (2019) Preoperative somatostatin analogues in patients with newly-diagnosed acromegaly: a systematic review and meta-analysis of comparative studies. Sci Rep 9:14070. https://doi.org/10.1038/s41598-019-50639-6
doi: 10.1038/s41598-019-50639-6 pubmed: 31575930 pmcid: 6773739
Albarel F, Cuny T, Graillon T et al (2022) Preoperative medical treatment for patients with acromegaly: yes or no? J Endocr Soc 6:bvac114. https://doi.org/10.1210/jendso/bvac114
doi: 10.1210/jendso/bvac114 pubmed: 35965944 pmcid: 9368018
Daly AF, Tichomirowa MA, Petrossians P et al (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95:E373–E383. https://doi.org/10.1210/jc.2009-2556
doi: 10.1210/jc.2009-2556 pubmed: 20685857
Chahal HS, Trivellin G, Leontiou CA et al (2012) Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 97:E1411–E1420. https://doi.org/10.1210/jc.2012-1111
doi: 10.1210/jc.2012-1111 pubmed: 22659247
Peverelli E, Treppiedi D, Giardino E et al (2015) Dopamine and somatostatin analogues resistance of pituitary tumors: focus on cytoskeleton involvement. Front Endocrinol 6:187. https://doi.org/10.3389/fendo.2015.00187
doi: 10.3389/fendo.2015.00187
Gatto F, Biermasz NR, Feelders RA et al (2016) Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. Eur J Endocrinol 174:651–662. https://doi.org/10.1530/EJE-15-0391
doi: 10.1530/EJE-15-0391 pubmed: 26888629
Fougner SL, Lekva T, Borota OC et al (2010) The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab 95:2334–2342. https://doi.org/10.1210/jc.2009-2197
doi: 10.1210/jc.2009-2197 pubmed: 20335450
Henriques DG, Miranda RL, Dezonne RS et al (2023) miR-383-5p, miR-181a-5p, and miR-181b-5p as predictors of response to first-generation somatostatin receptor ligands in acromegaly. Int J Mol Sci 24:2875. https://doi.org/10.3390/ijms24032875
doi: 10.3390/ijms24032875 pubmed: 36769196 pmcid: 9918086

Auteurs

Shin Urai (S)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Masaaki Yamamoto (M)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. yamamasa@med.kobe-u.ac.jp.
ORCID: 0000-0002-7000-8134

Naoki Yamamoto (N)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Masaki Suzuki (M)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Hiroki Shichi (H)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Keitaro Kanie (K)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Yasunori Fujita (Y)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Hironori Bando (H)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Hospital, Kobe, Japan.

Hidenori Fukuoka (H)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Hospital, Kobe, Japan.

Michiko Takahashi (M)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Hospital, Kobe, Japan.
Department of Nutrition, Kobe University Hospital, Kobe, Japan.

Genzo Iguchi (G)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Medical Center for Student Health, Kobe University, Kobe, Japan.
Division of Biosignal Pathophysiology, Kobe University, Kobe, Japan.

Yutaka Takahashi (Y)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Department of Diabetes and Endocrinology, Nara Medical University, Kashihara, Japan.

Wataru Ogawa (W)

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Classifications MeSH